Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/20/2025

Treatment for Stage III Uterine Carcinoma

Primary Surgical Management

  • The National Comprehensive Cancer Network recommends comprehensive surgical staging and maximal cytoreduction for all stage III patients, including total hysterectomy with bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, peritoneal cytology, resection of all visible extrauterine disease when feasible, and omentectomy if ovaries are involved 4, 5, 6

Adjuvant Treatment by Stage III Substage

  • For stage IIIA disease with ovarian involvement or positive peritoneal cytology only, abdomino-pelvic radiotherapy is the standard treatment, with external pelvic radiotherapy as an alternative option, and additional systemic chemotherapy should be considered in certain patients 4, 7, 8
  • For stage IIIA disease with multiple extrauterine sites, abdomino-pelvic radiotherapy is standard, and combined chemotherapy and radiotherapy provides the highest 5-year overall survival 2, 3, 4, 7, 8

Systemic Chemotherapy Regimens

  • The preferred chemotherapy regimen is carboplatin/paclitaxel for 3-6 cycles, which represents an efficacious, lower-toxicity alternative to older regimens, with cisplatin/doxorubicin with or without paclitaxel as an alternative but with greater toxicity 1, 2, 6
  • Chemotherapy alone results in a 2.2-fold increased risk of recurrence and 4.0-fold increased risk of death compared to combined modality therapy 1, 2

Evidence for Combined Modality Therapy

  • The PORTEC-3 trial demonstrated that combined chemoradiotherapy versus radiotherapy alone significantly improved outcomes, with 5-year overall survival of 81.4% versus 76.1% (HR 0.70, P=0.034) and 5-year failure-free survival of 76.5% versus 69.1% (HR 0.70, P=0.016) 1, 2, 3
  • Stage III patients benefited most from the addition of systemic therapy, with a significant reduction in recurrence risk and death risk compared to radiotherapy alone 1, 2, 3

Molecular Subtype Considerations

  • Molecular profiling impacts treatment benefit, with p53 abnormal tumors showing improved 5-year recurrence-free survival with chemoradiotherapy versus radiotherapy alone (59% vs 36%) 1, 3
  • POLE mutated tumors have excellent outcomes with either approach (100% vs 97%), while MMR-deficient tumors show less clear benefit (68% vs 76%) 1, 3

Common Pitfalls to Avoid

  • Single-modality treatment for stage III disease should be avoided, as chemotherapy alone results in higher pelvic failure rates and radiotherapy alone results in more frequent distant metastases, while combined therapy addresses both local and systemic disease 1, 2, 3
  • Whole abdominal radiotherapy as single modality is inferior to chemotherapy and excessively toxic, and is no longer recommended 1, 2, 3

REFERENCES

1

cancer of the endometrium. [LINK]

British Journal of Cancer, 2001

2

cancer of the endometrium. [LINK]

British Journal of Cancer, 2001

3

Management of Grade 2 Endometrial Adenocarcinoma [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

cancer of the endometrium. [LINK]

British Journal of Cancer, 2001

5

cancer of the endometrium. [LINK]

British Journal of Cancer, 2001

6

uterine neoplasms, version 1.2023, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2023

7

uterine neoplasms, version 1.2023, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2023

8

uterine neoplasms, version 1.2023, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2023